853 results about "In vitro experiment" patented technology

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

The invention relates to application of a targeted inhibition circPDK1 reagent in preparation of an anti-esophageal cancer drug, and belongs to the field of biological medicines. The reagent for targeted inhibition of circPDK1 expression provided by the invention is shRNA or siRNA, and in-vivo and in-vitro experiments prove that the reagent can significantly inhibit circPDK1 expression and inhibit growth and migration of esophageal cancer tumor cells; after siRNA of targeted annular circPDK1 is packaged into efficient and low-toxicity LNP-siRNA, circPDK1 expression is specifically silenced, proliferation and migration of esophageal cancer tumors can be remarkably inhibited, and a basis is provided for clinical treatment and scientific research of esophageal cancer related circRNA.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses an application of isorhamnetin-3-O-neohesperidin in preparation of a medicine for preventing and / or treating benign prostatic hyperplasia. In-vitro experiments show that the isorhamnetin-3-O-neohesperidin can inhibit proliferation of prostatic hyperplasia cells, promote apoptosis of the prostatic hyperplasia cells and regulate inflammatory response of the prostatic hyperplasia cells, and rat experiments show that the isorhamnetin-3-O-neohesperidin can improve the hormone endocrine disorder condition of an animal model body, and can inhibit the prostatic hyperplasia cells and promote the prostatic hyperplasia cell apoptosis and regulate the inflammatory response of the prostatic hyperplasia cells. The anti-inflammatory ability of an animal model is enhanced, and the traditional Chinese medicine composition has a relatively good treatment effect on prostatic hyperplasia caused by testosterone propionate. The medicine for preventing and / or treating benign prostatic hyperplasia, provided by the invention, contains a pharmacodynamic dose of isorhamnetin-3-O-neohesperidin and a pharmaceutically acceptable carrier or auxiliary material, can be prepared into a medicine dosage form which is convenient for clinical use and can play an optimal curative effect, and has a relatively high clinical application value.

The invention relates to a preparation method of an effective part extract of n-butyl alcohol of Eupatorium chinense and application of the effective part extract in treatment of diabetes complicated with depression. The technical scheme of the invention is to provide an extract of the n-butyl alcohol effective part of the eupatorium chinense, which can be used for treating diabetes complicated by depression diseases. In-vitro experiments show that the eupatorium chinense extract has an inhibition effect on acetylcholin esterase (AChE). In-vivo animal experiments find that classical anti-diabetes and depression treatment drugs, namely metformin hydrochloride and fluoxetine hydrochloride, are taken as positive controls, experimental research on the treatment effect of the effective part extract of the n-butyl alcohol of the eupatorium chinense on mice suffering from diabetes complicated with depression is developed, and research results show that the extract can regulate insulin resistance and can be used for treating diabetes complicated with depression. The glycometabolism of mice with diabetes mellitus complicated with depression is improved, and the depression symptom is improved. The extract has a remarkable effect of treating diabetes mellitus complicated with depression, has a good effect of treating diabetes mellitus complicated with depression, and is expected to be developed into a new natural medicine for treating diabetes mellitus complicated with depression.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention discloses a moisturizer prepared from a lysate extract produced by fermentation of bacillus subtilis. The hydroxydecyl ubiquinone is identified in Y-3FLE, and the yield of the hydroxydecyl ubiquinone is 0.45 mu g / g after the hydroxydecyl ubiquinone is cultured for 4 days, so that the quinone substances are identified in the Halophilic bacteria in the Yuncheng Salt Lake for the first time. The Y-3FLE is prepared by adopting absolute ethyl alcohol as a solvent, the oxidation resistance of the Y-3FLE is investigated through an in-vitro experiment, and a result shows that the Y-3FLE is relatively high in reducing capacity and relatively high in oxidation resistance. A human body closed patch test result shows that the Y-3FLE has no obvious irritation to human skin. The method is applied to the moisturizer, and human body efficacy evaluation is carried out through a multi-probe skin tester. Results show that the moisturizer added with 1% of Y-3FLE has multiple remarkable effects of moisturizing, repairing, nourishing and the like.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention belongs to the technical field of biological medicine, and particularly relates to application of chlorbuconazole or salt thereof in preventing, relieving or treating diseases related to HIF-2alpha. In-vitro experiments prove that the chlorbuconazole enhances the transcriptional activity of HIF-2alpha so as to promote the expression of downstream genes regulated and controlled by the HIF-2alpha; it is proved that chlorburazol has the effects of increasing erythropoiesis and relieving renal injury on an aristolochic acid-induced zebra fish chronic kidney disease model, a cisplatin-caused acute kidney injury and renal anemia model and a unilateral ureteral obstruction model. Meanwhile, the traditional Chinese medicine composition belongs to new use of old medicines, so that the medicine research and development cost and the treatment cost are saved, and the traditional Chinese medicine composition has obvious economic benefits and clinical application values.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention belongs to the technical field of biology, and particularly relates to a monoclonal antibody combined with a human IL-8 antigen and application of the monoclonal antibody. A heavy chain CDR region of the monoclonal antibody comprises a CDR1 of which the amino acid sequence is as shown in SEQ ID NO.5, a CDR2 of which the amino acid sequence is as shown in SEQ ID NO.6 and a CDR3 of which the amino acid sequence is as shown in SEQ ID NO.7; a light chain CDR region of the monoclonal antibody comprises a CDR4 of which the amino acid sequence is shown as SEQ ID NO.8, a CDR5 of which the amino acid sequence is shown as SEQ ID NO.9 and a CDR6 of which the amino acid sequence is shown as SEQ ID NO.10. The monoclonal antibody can specifically bind to human IL-8, and has good affinity. In-vitro experiments prove that the compound can be used for diagnosing and treating IL-8-mediated related diseases.

The present invention discloses an anti-non-small cell lung cancer active birch inonotus polysaccharide IOP-1 and its application, belonging to the field of biomedicine. The present invention adopts a method of boiling water extraction and ethanol precipitation of birch inonotus polysaccharide, and combines DEAE cellulose column purification technology, and utilizes the principle that macromolecular polysaccharides are insoluble in organic solvents to successfully achieve the separation of birch inonotus polysaccharide and obtain a birch inonotus polysaccharide IOP-1 with anti-non-small cell lung cancer activity, wherein the monosaccharide composition of the birch inonotus polysaccharide IOP-1 includes fucose, rhamnose, arabinose, galactose, glucose, xylose and mannose with a molar mass ratio of 2.41:0.58:1.03:2.17:82.20:4.33:7.29. Its significant effect against non-small cell lung cancer was verified by in vitro and in vivo experiments, providing a new treatment method for the clinical treatment of non-small cell lung cancer.

The present invention discloses a black chicken liver hydrolyzed peptide that can be used to improve ulcerative colitis, and its preparation method and application, which belong to the field of biomedicine technology. The preparation method of the black chicken liver hydrolyzed peptide comprises the following steps: making black chicken liver into minced meat and mixing it with water, heating the obtained liquid material, adding alkaline protease for enzymatic hydrolysis, inactivating the enzyme and collecting the supernatant by centrifugation, and freeze-drying to obtain the black chicken liver hydrolyzed peptide. The present invention adopts formaldehyde titration to detect the degree of hydrolysis, adopts SDS-PAGE electrophoresis and Tricine-SDS-PAGE electrophoresis to detect the molecular weight, performs sequence analysis by LC-MS / MS, uses a database to predict the biological function of peptide segments, detects the antioxidant and blood pressure lowering ability of black chicken liver peptide by in vitro experiments, and detects the effect of black chicken liver peptide in improving colitis by mouse experiments. The results show that the black chicken liver peptide prepared by the present invention has the advantages of antioxidant, blood pressure lowering and improvement of ulcerative colitis.

The invention discloses a preparation method of a mycotoxin degrading enzyme intelligent slow-release feed additive, and relates to the technical field of feed additive production, a double-emulsion embedding technology is adopted, enzyme is embedded in a multi-layer shell composed of chitosan, sodium alginate and an enteric polymer Eudragit S100, and then Ca < 2 + > ion cross-linking solidification is performed to obtain the mycotoxin degrading enzyme intelligent slow-release feed additive. And finally, freeze-drying or spray-drying to obtain the core-shell structure microcapsule. The obtained microcapsules are compounded with functional carriers such as yeast cell walls, sodium aluminosilicate, mannan oligosaccharide, talcum powder and the like to prepare finished products which can be directly added into various feeds. The release rate of the additive in simulated gastric juice with the pH value of 2.0 for 4 hours is lower than 15%, the release rate of the additive in simulated intestinal juice with the pH value of 6.8 for 6 hours exceeds 90%, the enzyme activity can be effectively protected, and targeted release of intestinal tracts is achieved; meanwhile, the compound carrier has a synergistic adsorption effect on various mycotoxins, and the degradation rates of aflatoxin B1, zearalenone and ochratoxin A in an in-vitro experiment respectively reach 87% or above.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The present invention discloses a preparation method of Inonotus hispidus polysaccharide IHP-1aa: It is obtained by removing fat with ethanol, extracting with water and precipitating with ethanol, then removing proteins by the Sevage method, separating neutral polysaccharide components through a DEAE-52 cellulose column and a DEAE agarose gel column, and finally purifying with Sephadex G-100. The Inonotus hispidus polysaccharide has uniform purity and clear composition, and is a heteropolysaccharide composed of glucose, galactose, mannose, fucose and methylgalactose, with a molecular weight of 26.9 kDa. In vitro experiments show that it has no adverse effects on normal cells, can significantly stimulate macrophages RAW264.7 to secrete NO, IL-6 and TNF-α, has good immunomodulatory activity, and can be used for the development of immunomodulatory products.

The invention relates to the technical field of biology, in particular to a preparation method and application of a recombinant human long-acting interleukin-22 binding protein. The amino acid sequence of the recombinant human long-acting interleukin-22 binding protein is as shown in SEQ ID No. 1. According to the method for preparing the IL-22BP recombinant protein with high biological activity by utilizing an Escherichia coli prokaryotic expression system, a novel fusion protein is designed, a sequence for coding human IL-22BP is connected with a sequence for coding ABD to construct an IL-22BP-ABD fusion gene, the IL-22BP-ABD fusion gene is induced to be expressed in Escherichia coli, inclusion body protein is separated, and the IL-22BP recombinant protein with high biological activity is obtained. The target protein is obtained through denaturation, purification and renaturation, and the biological activity of the IL-22BP-ABD is verified through in-vivo and in-vitro experiments.

The invention discloses a method for screening breast cancer biomarkers based on weighted gene co-expression network analysis and application. High-expression keratin KRT5 and low-expression ubiquitin coupling enzyme UBE2C in breast cancer patients are screened out and are closely related to good prognosis of the high-expression keratin KRT5 and the low-expression ubiquitin coupling enzyme UBE2C, and the KRT5 and the UBE2C are effective molecular markers for breast cancer early-stage diagnosis and prognosis analysis. In-vitro experiments show that the development process of the breast cancer can be effectively inhibited by promoting the expression of the KRT5 gene and inhibiting the expression of the UBE2C gene. According to the invention, early-stage diagnosis and prognosis analysis of breast cancer can be rapidly carried out, a new direction is provided for diagnosis, treatment and prognosis of breast cancer, and development of individualized treatment is promoted.

The invention discloses application of an SUMO inhibitor 2-D08 in preparation of drugs for treating chronic myelogenous leukemia (CML) and drug resistance of a tyrosine kinase inhibitor (TKI) of the SUMO inhibitor 2-D08. It is revealed for the first time that SUMOylation modification drives disease progression by stabilizing BCR-ABL protein, 2-D08 promotes BCR-ABL protein degradation by inhibiting the modification, and leukemia cell proliferation is remarkably inhibited. In-vitro experiments prove that the compound effectively inhibits the activity of TKI drug-resistant cells, and in-vivo experiments show that 5 mg / kg of the compound can improve liver and spleen infiltration of CML mice. The inhibitor provides a new scheme for overcoming drug resistance, and fills the application blank of SUMOylation modification in CML treatment.

The invention discloses application of a CXCL14 combined immune checkpoint inhibitor in treatment of spinal glioma. The immune checkpoint inhibitor is selected from a PD-1 inhibitor or a combination of the PD-1 inhibitor and a CTLA4 inhibitor. In-vivo and in-vitro experiments prove that the CXCL14 combined with the PD-1 inhibitor, the CXCL14 combined with the PD-1 inhibitor and the CTLA4 inhibitor can be used for remarkably inhibiting the growth of mutant spinal glioma and have a remarkable synergistic effect. The invention provides a new strategy for treatment of spinal glioma, and is widely applied clinically.

The invention relates to a polypeptide capable of promoting tuft cell proliferation and application of the polypeptide in treatment of inflammatory bowel diseases, in particular to a polypeptide Sjp40-73 derived from schistosome egg protein, and the amino acid sequence of the polypeptide Sjp40-73 is SEQ ID NO.1. The invention further relates to a preparation method of the polypeptide Sjp40-73. The polypeptide can be obtained through methods such as genetic engineering expression or chemical synthesis. In-vitro experiments prove that the peptide can effectively increase the number of tuft cells of intestinal organs of mice; in-vivo experiments further prove that the peptide can relieve mouse inflammatory bowel diseases and can improve corresponding inflammations. The polypeptide prepared by the invention can be applied to medicines, health-care products or food additives for preventing and treating inflammatory enteritis.

The present invention provides an anti-glycation efficacy testing method, comprising: defining several areas on the skin surface as control areas and test sample areas, respectively, collecting initial skin color parameters; applying a control substance and a test sample to the control area and the test sample area, respectively; applying a test composition containing reducing sugars to the control area and the test sample area; collecting skin color parameters again at a specified time point; respectively calculating the change rate of the skin color parameters in the test sample area and the change rate of the skin color parameters in the control area, and comparing them. The testing method of the present invention can accurately evaluate the anti-glycation effect of cosmetics in vivo without trauma and intervention, eliminating the deviation caused by factors such as age, skin quality, and ethnicity in the deduction from in vitro experiments to actual use effects.

The invention discloses stropharia rugoso-annulata polysaccharide as well as a preparation method and application thereof. The monosaccharide of the stropharia rugoso-annulata polysaccharide disclosed by the invention comprises glucose, galactose, mannose and galacturonic acid; the weight-average molecular weight of the stropharia rugoso-annulata polysaccharide is 1.4712 * 10 < 4 > to 1.623 * 10 < 4 > Da; the main chain of the stropharia rugoso-annulata polysaccharide contains-> 6)-alpha-D-(O-Me)-Galp-(1->, 1, 6-Glc, 1, 3-Man and 1.3-Gal exist in the main chain or a side chain, and terminal residues contain T-Glc and T-Gal. According to the invention, by constructing a DSS induced UC mouse model, the influence of Stropharia rugosoannulata polysaccharide (SRP1) on UC mice is investigated. Results show that the stropharia rugoso-annulata polysaccharide has a certain treatment effect on ulcerative colitis. In-vivo experiments show that the stropharia rugoso-annulata polysaccharide disclosed by the invention can increase abundance of bacteroides and thick-wall funguses and reduce abundance of proteobacteria and deferribacterium funguses; in-vitro experiments show that the stropharia rugoso-annulata polysaccharide can increase the abundance of beneficial bacteria bacteroides, reduce the abundance of harmful bacteria Escherichia-Shigella and Enterococcus, and increase the content of short-chain fatty acids.

The invention relates to a pH-responsive copper hydrogen phosphate-loaded hydrogel with multiple enzyme-like activities and a preparation method and application thereof. The material mainly shows catalase-like activity in a neutral microenvironment, and can remove H2O2 and relieve oxidative stress; in a weakly acidic microenvironment, the compound mainly shows peroxidase-like activity and catalyzes H2O2 to generate. OH bacteria with higher toxicity; meanwhile, the inherent osteogenesis promoting performance of copper synergistically enhances bone regeneration, the biocompatibility, the oxidation resistance, the osteogenesis promoting capacity under the oxidative stress condition and the antibacterial efficiency under the weak acid condition of the SA / CuHP hydrogel are evaluated through in-vitro experiments, and a type II diabetes rat periodontitis model is established; the in-vivo antibacterial and osteogenesis promoting effects and the biological safety performance of the compound are verified, and a new strategy is provided for treatment of periodontitis with diabetes mellitus.

The invention discloses construction and application of a streptococcus suis serotype 2 cps2C gene knockout mutant strain. The invention relates to a streptococcus suis serotype 2 cps2C gene knockout mutant strain 05ZYH33 delta cps2C. A coding gene, from the 31st site to the 1000th site, of the cps2C gene in the strain 05ZYH33 is replaced by a spectinomycin resistance gene cassette SpcR. The mutant strain 05ZYH33 delta cps2C is applied to preparation of a streptococcus suis type 2 attenuated vaccine and a subunit vaccine. The capsule of the mutant strain 05ZYH33 delta cps2C is obviously reduced; in-vitro experiments show that the macrophage phagocytosis resistance of the mutant strain 05ZYH33 delta cps2C is reduced, and animal toxicity test results show that the toxicity of the mutant strain is obviously reduced. The mutant strain provides an important clue for screening of protective antigens of multivalent subunit vaccines, and can be applied to development of S.suis attenuated vaccines and multivalent subunit vaccines.

The invention discloses a composition based on an engineered stem cell exosome and application of the composition in treating male sexual dysfunction. The composition comprises a mesenchymal stem cell exosome modified by genetic engineering, and the surface of the mesenchymal stem cell exosome displays a bifunctional fusion polypeptide targeting TbetaR II and LOXL2. According to the fusion polypeptide, TbetaR-PEP and LOXL2-PEP are integrated through a flexible linker, and an HIV-TAT penetrating peptide and a self-assembly motif are introduced, so that nanoparticles are formed, and the half-life period is prolonged. In-vitro experiments show that the inhibition efficiency of the fusion polypeptide on TbetaRII and LOXL2 is obviously superior to that of a single peptide, and the fusion polypeptide can synergistically reverse fibrosis and promote angiogenesis. Animal experiments prove that the exosome loaded with the fusion polypeptide can significantly improve the erectile function of diabetic ED rats. According to the invention, a radical treatment scheme is provided for male sexual dysfunction through double-target cooperation, long-acting delivery and a multi-effect repair mechanism.

The invention discloses lactobacillus johnsonii A21065 capable of resisting oxidation, prolonging life and delaying Parkinson's disease as well as a product and application of the lactobacillus johnsonii A21065, and belongs to the technical field of functional strains. The preservation number of the lactobacillus johnsonii A21065 is GDMCC (China General Microbiological Culture Collection Center) No: 65767. In a caenorhabditis elegans model, the lactobacillus johnsonii A21065 shows that the lactobacillus johnsonii A21065 has better effects of improving the oxidation resistance of nematodes, resisting environmental stress and prolonging the life, also shows a good effect in in-vitro experiments of resisting artificial gastrointestinal fluid, resisting cholate and the like, meanwhile, the lactobacillus johnsonii A21065 also has an effect of improving the cognition of a Parkinson nematode model, and the lactobacillus johnsonii A21065 has a good application prospect. The invention has important significance for preventing and / or treating Parkinson's disease.

The present invention discloses roxburghii polysaccharide and its preparation method and application. Wherein roxburghii crude polysaccharide is purified to obtain two polysaccharides RP1 and RP3, RP1 monosaccharide types include galacturonic acid, galactose, rhamnose and arabinose, and its molar ratio is 1.00:3.45:1.88:1.82, RP3 monosaccharide types include galactose, rhamnose and arabinose, galacturonic acid, galactose, rhamnose and arabinose, and its molar ratio is 1.00:0.37:0.37:0.25. It has been confirmed by in vitro experiments that the above-mentioned roxburghii polysaccharide has the ability to significantly inhibit the proliferation of MCF-7 breast cancer cells, as well as the effect of inducing apoptosis of MCF-7 breast cancer cells, and can be developed to prepare breast cancer therapeutic drugs; At the same time, the above-mentioned roxburghii polysaccharide has no effect on normal L929 cells. Therefore, the above-mentioned roxburghii polysaccharide has broad application prospects and has good social and economic benefits.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

The invention discloses a pressure-controlled bovine bone collagen active peptide, and belongs to the field of food. A potential ACE inhibitory peptide is rapidly screened through a bioinformatics method, the ACE inhibitory activity of the bovine bone collagen peptide is verified in combination with an in-vitro experiment, IC50 values of the screened bovine bone collagen active peptides LGALPGF, VFPGLL and AAAALGPW to ACE are 32.07 mu M, 40.41 mu M and 77.68 mu M respectively, and the peptide with the sequence is proved to have a good antihypertensive function.